Ketotifen Stulln 0,25 Mg/Ml Augentropfen Pharma Stulln (Ketotifen)

Ketotifen works by stabilising mast cells, which prevents the release of histamine and other inflammatory mediators. It also blocks histamine H1 receptors on the surface of the eye, reducing vasodilation, vascular permeability, and nerve stimulation that cause itching and redness.

The specific dosing regimen for Ketotifen Stulln eye drops is determined by the prescribing healthcare professional based on the severity of the allergic condition and the patient’s response. Patients should follow the prescriber’s instructions and not alter the dose on their own.

The safety of ketotifen eye drops during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Ketotifen combines mast‑cell stabilisation with H1‑receptor antagonism, offering both preventive and symptomatic relief. Some other ocular antihistamines act only as H1 blockers, providing symptom control without the mast‑cell stabilising effect. The choice depends on the clinician’s assessment of efficacy, tolerability and patient needs.

Ketotifen Stulln eye drops should be stored at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from light and moisture, and discard any product that appears discoloured or contaminated.

The patient should wash their hands, tilt the head back, and gently pull down the lower eyelid to create a small pocket. One drop is placed into the conjunctival sac of the affected eye(s). The eye should be closed gently for a few seconds to allow distribution, and contact lenses should be removed before instillation.

Serious risks, although rare, include severe allergic reactions such as anaphylaxis, corneal ulceration, and a significant increase in intra‑ocular pressure that could lead to glaucoma. Patients should seek immediate medical attention if they experience sudden vision loss, intense eye pain, swelling of the eyelids, or any signs of infection.

Individuals with a known hypersensitivity to ketotifen or any of the formulation’s excipients should not use the product. Caution is also advised for patients with uncontrolled glaucoma, severe ocular infections, or those who are pregnant or breastfeeding without a clear benefit‑risk assessment by their clinician.